MiiHealth AI raises $2.8M seed to expand AI-powered patient intake across independent practices

Patient intake automation is a fundamentally different market segment than the high-profile ambient documentation and clinical decision support categories that attract larger rounds and more coverage. Intake automation targets the front-of-visit administrative workflow rather than the clinical workflow, and its primary buyer is independent and small-group practices — not health systems with IT departments and implementation capacity.

That market reality shapes what a $2.8M seed can accomplish. Independent practices buy on price, simplicity, and word-of-mouth. A practice management software integration that reliably automates insurance verification and pre-visit history capture — and that a solo practitioner can implement without an IT consultant — has a real market. The challenge is distribution, not technology: reaching thousands of independent practices at reasonable customer acquisition cost.

The broader category MiiHealth is entering has several well-funded incumbents — Tebra, Phreesia, and the larger practice management platforms have all built intake automation capabilities. The independent-practice niche is underserved by the enterprise-first vendors, which is MiiHealth’s positioning argument. Whether the company can build a distribution channel fast enough to reach that niche before the large platforms commoditize the capability is the standard startup-vs-incumbent question.

At $2.8M seed, the funding is sized for product development and early customer acquisition rather than full market expansion. A Series A will be needed within 18 months if the company demonstrates unit economics that support scaling.